愛污传媒

Skip to main content

Drug used in diabetes treatment Mounjaro helped dieters shed 27 kg, study finds

Share

The medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight, or about 27 kilograms (60 pounds) on average, when combined with intensive diet and exercise, a new study shows.

By comparison, a group of people who also dieted and exercised, but then received dummy shots, lost weight initially but then regained some, researchers reported Sunday in the

"This study says that if you lose weight before you start the drug, you can then add a lot more weight loss after," said Dr. Thomas Wadden, a University of Pennsylvania obesity researcher and psychology professor who led the study.

The results, which were also presented Sunday at a medical conference, confirm that the drug made by Eli Lilly & Co. has the potential to be one of the most powerful medical treatments for obesity to date, outside experts said.

"Any way you slice it, it's a quarter of your total body weight," said Dr. Caroline Apovian, who treats obesity at Brigham and Women's Hospital and wasn't involved in the study.

The injected drug, tirzepatide, was approved in the U.S. in May 2022 to treat diabetes. Sold as Mounjaro, it has been used "off-label" to treat obesity, joining a frenzy of demand for diabetes and weight-loss medications including Ozempic and Wegovy, made by Novo Nordisk.

All the drugs, which carry retail price tags of US$900 a month or more, have been in shortage for months.

Tirzepatide targets two hormones that kick in after people eat to regulate appetite and the feeling of fullness communicated between the gut and the brain. Semaglutide, the drug used in Ozempic and Wegovy, targets one of those hormones.

The new study, which was funded by Eli Lilly, enrolled about 800 people who had obesity or were overweight with a weight-related health complication -- but not diabetes. On average, study participants weighed about 109.5 kilograms (241 pounds) to start and had a body-mass index -- a common measure of obesity -- of about 38.

After three months of intensive diet and exercise, more than 200 participants left the trial, either because they failed to lose enough weight or for other reasons. The remaining nearly 600 people were randomized to receive tirzepatide or a placebo via weekly injections for about 16 months. Nearly 500 people completed the study.

Participants in both groups lost about 7 per cent of their body weight, or almost 8 kilograms (17 pounds), during the diet-and-exercise phase. Those who received the drug went on to lose an additional 18.4 per cent of initial body weight, or about 20 kilograms (44 pounds) more, on average. Those who received the dummy shots regained about 2.5 per cent of their initial weight, or 2.7 kilograms (6 pounds.)

Overall, about 88 per cent of those taking tirzepatide lost 5 per cent or more of their body weight during the trial, compared with almost 17 per cent of those taking placebo. Nearly 29 per cent of those taking the drug lost at least a quarter of their body weight, compared with just over 1 per cent of those taking placebo.

That's higher than the results for semaglutide and similar to the results seen with bariatric surgery, said Apovian.

"We're doing a medical gastric bypass," she said.

Side effects including nausea, diarrhea and constipation were reported more frequently in people taking the drug than those taking the placebo. They were mostly mild to moderate and occurred primarily as the dose of the drug was escalated, the study found. More than 10 per cent of those taking the drug discontinued the study because of side effects, compared with about 2 per cent of those on placebo.

Lilly is expected to publish the results soon of another study that the firm says shows similar high rates of weight loss. The U.S. Food and Drug Administration has granted the company a fast-track review of the drug to treat obesity, which Eli Lilly may sell under a different brand name. A decision is expected by the end of the year.

------

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.

CTVNews.ca Top Stories

Israel launches strikes on military targets in Iran, escalating Mideast wars

Israel pounded Iran with a series of airstrikes early Saturday, saying it was targeting military targets in retaliation for the barrage of ballistic missiles the Islamic Republic fired upon Israel earlier this month. Explosions could be heard in the Iranian capital, Tehran, though there was no immediate information on damage or casualties.

Canada Post driver Rick Harper recounts how he and others helped save a woman from a Tesla that caught fire after crashing into a guardrail on Lake Shore Boulevard.

Local Spotlight

A new resident at a Manitoba animal rescue has waddled her way into people's hearts.

Hundreds of people ran to the music of German composer and pianist Beethoven Wednesday night in a unique race in Halifax.

He is a familiar face to residents of a neighbourhood just west of Roncesvalles Avenue.

A meteor lit up our region's sky last night 鈥 with a large fireball shooting across the horizon over Lake Erie at around 7:00 p.m.

Residents of Ottawa's Rideauview neighbourhood say an aggressive wild turkey has become a problem.

A man who lost his life while trying to rescue people from floodwaters, and a 13-year-old boy who saved his family from a dog attack, are among the Nova Scotians who received a medal for bravery Tuesday.

A newly minted Winnipegger is hoping a world record attempt will help bring awareness for the need for more pump track facilities in the city.

A Springfield, Ont. man is being hailed a 'hero' after running into his burning home to save his two infant children.

Hortense Anglin was the oldest graduate to make her way across the platform at York University's Fall Convocation ceremony this week. At the age of 87, she graduated with an Honours degree in Religious Studies.